Detalhe da pesquisa
1.
Disruption of mitochondrial complex I induces progressive parkinsonism.
Nature
; 599(7886): 650-656, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34732887
2.
Author Correction: Disruption of mitochondrial complex I induces progressive parkinsonism.
Nature
; 603(7899): E1, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35149834
3.
Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease.
Proc Natl Acad Sci U S A
; 114(11): E2253-E2262, 2017 03 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-28246328
4.
Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo.
Proc Natl Acad Sci U S A
; 111(27): 9977-82, 2014 Jul 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-24979780
5.
Chronic Nicotine Exposure Attenuates Methamphetamine-Induced Dopaminergic Deficits.
J Pharmacol Exp Ther
; 355(3): 463-72, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26391161
6.
Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure.
J Pharmacol Exp Ther
; 340(2): 295-303, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22034657
7.
Methamphetamine self-administration acutely decreases monoaminergic transporter function.
Synapse
; 66(3): 240-5, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22120988
8.
Methamphetamine treatment during development attenuates the dopaminergic deficits caused by subsequent high-dose methamphetamine administration.
Synapse
; 65(8): 771-7, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21190217
9.
Dopamine metabolism by a monoamine oxidase mitochondrial shuttle activates the electron transport chain.
Nat Neurosci
; 23(1): 15-20, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31844313
10.
Author Correction: Dopamine metabolism by a monoamine oxidase mitochondrial shuttle activates the electron transport chain.
Nat Neurosci
; 23(2): 293, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31911656
11.
The Synaptic Vesicle Glycoprotein 2: Structure, Function, and Disease Relevance.
ACS Chem Neurosci
; 10(9): 3927-3938, 2019 09 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-31394034
12.
Immunochemical analysis of the expression of SV2C in mouse, macaque and human brain.
Brain Res
; 1702: 85-95, 2019 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29274878
13.
Selective D2 and D3 receptor antagonists oppositely modulate cocaine responses in mice via distinct postsynaptic mechanisms in nucleus accumbens.
Neuropsychopharmacology
; 44(8): 1445-1455, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30879021
14.
Immunochemical localization of vesicular monoamine transporter 2 (VMAT2) in mouse brain.
J Chem Neuroanat
; 83-84: 82-90, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27836486
15.
Alteration to Dopaminergic Synapses Following Exposure to Perfluorooctane Sulfonate (PFOS), in Vitro and in Vivo.
Med Sci (Basel)
; 4(3)2016 Aug 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-29083377
16.
Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals.
Toxicol Sci
; 153(1): 79-88, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27287315
17.
Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration.
Exp Neurol
; 275 Pt 1: 17-24, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26428905
18.
Selective Enhancement of Dopamine Release in the Ventral Pallidum of Methamphetamine-Sensitized Mice.
ACS Chem Neurosci
; 7(10): 1364-1373, 2016 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-27501345
19.
In Vitro and In Vivo Characterization of the Alkaloid Nuciferine.
PLoS One
; 11(3): e0150602, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26963248
20.
Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity.
ACS Chem Neurosci
; 6(5): 790-9, 2015 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25746685